Personalized medicine in cystic fibrosis: Dawning of a new era

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 7, 2012, Pages 593-597

  Clancy, John P ^a   Jain, Manu ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

CFTR; Corrector; Mutations; Potentiator; Suppressor

Indexed keywords

ATALUREN; IVACAFTOR; LUMACAFTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VX 661;

CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; FRAMESHIFT MUTATION; GENE THERAPY; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; LUNG CLEARANCE; MECONIUM ILEUS; NONHUMAN; PANCREAS FUNCTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; STEATORRHEA; STOP CODON; SWEAT TEST;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION;

EID: 84866097633     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201204-0785PP     Document Type: Review

References (49)

1. Busch R. On the history of cystic fibrosis. Acta Univ Carol [Med] (Praha) 1990;36:13-15.
2. Alonso Y De Los Ruyzes De Fonteca J. Diez previlegios para mgeres prenadas. Alcala de Henares 1606:212.
3. Garrod AE, Hurtley WH. Congenital family steatorrhea. Q J Med 1912;6:242-258.
4. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 1938;56:344-399.
5. Di Sant'Agnese PA, Darling RC, Perera GA, Shea E. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease. Pediatrics 1953;12:549-563.
6. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-1080. (Pubitemid 19231815)
7. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-1065. (Pubitemid 19231813)
8. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073. (Pubitemid 19231814)
9. Cystic Fibrosis Genetic Analysis Consortium. Cystic fibrosis mutation database. Toronto: Cystic Fibrosis Centre at the Hospital for Sick Children in Toronto; 1989.
10. Anderson MP, Gregory RJ, Thompson S, Souza DW, Paul S, Mulligan RC, Smith AE, Welsh MJ. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 1991;253:202-205. (Pubitemid 21917143)
11. Tang L, Fatehi M, Linsdell P. Mechanism of direct bicarbonate transport by the CFTR anion channel. J Cyst Fibros 2009;8:115-121.
12. Moskwa P, Lorentzen D, Excoffon KJ, Zabner J, McCray PB Jr, Nauseef WM, Dupuy C, Banfi B. A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med 2007;175:174-183. (Pubitemid 46115089)
13. Donaldson SH, Boucher RC. Sodium channels and cystic fibrosis. Chest 2007;132:1631-1636. (Pubitemid 350156022)
14. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001. (Pubitemid 40638370)
15. Varga K, Goldstein RF, Jurkuvenaite A, Chen L, Matalon S, Sorscher EJ, Bebok Z, Collawn JF. Enhanced cell-surface stability of rescued deltaf508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. Biochem J 2008;410:555-564. (Pubitemid 351429026)
16. Hwang TC, Wang F, Yang IC, Reenstra WW. Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol 1997;273:C988-C998. (Pubitemid 27422179)
17. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29:522-526. (Pubitemid 46372100)
18. Cystic Fibrosis Foundation. Patient registry annual report 2010. Bethesda, MD: Cystic Fibrosis Foundation; 2010.
19. Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011;183:1463-1471.
20. Levy L, Durie P, Pencharz P, Corey M. Prognostic factors associated with patient survival during nutritional rehabilitation in malnourished children and adolescents with cystic fibrosis. J Pediatr Gastroenterol Nutr 1986;5:97-102. (Pubitemid 17006374)
21. Ratjen F. Changes in strategies for optimal antibacterial therapy in cystic fibrosis. Int J Antimicrob Agents 2001;17:93-96. (Pubitemid 32103283)
22. Flume PA, Robinson KA, O'Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, White TB, Marshall BC. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009;54:522-537.
23. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30. (Pubitemid 29024680)
24. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNAse on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis: The Pulmozyme Study Group. N Engl J Med 1994;331:637-642. (Pubitemid 24276863)
25. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III. Azithromycin in patients with cystic fibrosis chronically infected with pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756. (Pubitemid 37430625)
26. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240. (Pubitemid 43113028)
27. Lebecque P, Leonard A, De Boeck K, De Baets F, Malfroot A, Casimir G, Desager K, Godding V, Leal T. Early referral to cystic fibrosis specialist centre impacts on respiratory outcome. J Cyst Fibros 2009;8:26-30.
28. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-928.
29. Quon BS, Goss CH. A story of success: continuous quality improvement in cystic fibrosis care in the USA. Thorax 2011;66:1106-1108.
30. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT, Danel C. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994;8:42-51.
31. Joseph PM, O'Sullivan BP, Lapey A, Dorkin H, Oren J, Balfour R, Perricone MA, Rosenberg M, Wadsworth SC, Smith AE, et al. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Hum Gene Ther 2001;12:1369-1382. (Pubitemid 32881343)
32. Griesenbach U, Geddes DM, Alton EW. Gene therapy progress and prospects: cystic fibrosis. Gene Ther 2006;13:1061-1067.
33. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009;106:18825-18830.
34. Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, Fritsch J, Hanssens L, Hirawat S, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010;182:1262-1272.
35. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003;349:1433-1441. (Pubitemid 37211058)
36. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996;2:467-469. (Pubitemid 26191920)
37. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010;363:1991-2003.
38. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-1672.
39. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP Jr, Urrutia A, Joubran J, Seepersaud S, Sussky K, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 2012;11:237-245.
40. Rowe SM, Clancy JP. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. BioDrugs 2009;23:165-174.
41. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372:719-727.
42. Clancy JP, Konstan MW, Rowe SM, Accurso F, Zeitlin P, Hirawat S. A phase II study of PTC124 in CF patients harboring premature stop mutations [abstract]. Pediatr Pulmonol 2006;41:A269.
43. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67:12-18.
44. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011;108:18843-18848.
45. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordonez CL, Geller DE. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest (In press)
46. Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, Tullis E, Martin S, Corey M, Tsui LC, Durie P. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006;174:787-794. (Pubitemid 44511660)
47. Rowe SM, Accurso F, Clancy JP. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc 2007;4:387-398. (Pubitemid 47330876)
48. Davis PB, Schluchter MD, Konstan MW. Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis. Pediatr Pulmonol 2004;38:204-209. (Pubitemid 39095677)
49. Bush A, Simmonds NJ. Hot off the breath: 'I've a cost for' - the 64 million dollar question. Thorax 2012;67:382-384.